234 related articles for article (PubMed ID: 25706395)
1. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia.
Ross K; Gillespie-Twardy AL; Agha M; Raptis A; Hou JZ; Farah R; Redner RL; Im A; Duggal S; Ding F; Lin Y; Boyiadzis M
Oncol Res; 2015; 22(2):85-92. PubMed ID: 25706395
[TBL] [Abstract][Full Text] [Related]
2. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
3. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Kantarjian H; O'brien S; Cortes J; Giles F; Faderl S; Jabbour E; Garcia-Manero G; Wierda W; Pierce S; Shan J; Estey E
Cancer; 2006 Mar; 106(5):1090-8. PubMed ID: 16435386
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
6. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.
Tasaki T; Yamauchi T; Matsuda Y; Takai M; Ookura M; Lee S; Tai K; Ikegaya S; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5631-6. PubMed ID: 25275066
[TBL] [Abstract][Full Text] [Related]
7. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
8. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Haznedaroglu IC; Sayınalp N; Aksu S; Ozcebe O; Goker H; Aydın MS; Buyukasık Y
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):729-734. PubMed ID: 31540855
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
10. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
[TBL] [Abstract][Full Text] [Related]
11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
12. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
14. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
15. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
16. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
17. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Wieduwilt MJ; Pawlowska N; Thomas S; Olin R; Logan AC; Damon LE; Martin T; Kang M; Sayre PH; Boyer W; Gaensler KML; Anderson K; Munster PN; Andreadis C
Clin Cancer Res; 2019 Aug; 25(16):4917-4923. PubMed ID: 31152020
[TBL] [Abstract][Full Text] [Related]
19. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]